Hedge Fund's Latest Patent Attack Targets Pharmacyclics
An organization tied to hedge fund manager Kyle Bass challenged yet another drug patent Monday, asking the Patent Trial and Appeal Board to invalidate a patent on Pharmacyclics Inc.'s cancer drug...To view the full article, register now.
Already a subscriber? Click here to view full article